BCR-ABL activity measured by 50% inhibitory concentration for
imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of
patients with chronic myeloid leukemia does not predict
treatment response.

J 2012

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

ŠIMARA, Pavel; Martina PETERKOVÁ; Stanislav STEJSKAL; Michaela POTĚŠILOVÁ; Irena KRONTORÁD KOUTNÁ et al.

Základní údaje

Originální název

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Autoři

ŠIMARA, Pavel; Martina PETERKOVÁ; Stanislav STEJSKAL; Michaela POTĚŠILOVÁ; Irena KRONTORÁD KOUTNÁ; Zdeněk RÁČIL; Filip RÁZGA; Tomáš JURČEK; Dana DVOŘÁKOVÁ a Jiří MAYER

Vydání

Leukemia & lymphoma, England, Informa Healthcare, 2012, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.301

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14330/12:00059688

Organizační jednotka

Fakulta informatiky

DOI

https://doi.org/10.3109/10428194.2012.656104

UT WoS

000306566000035

Klíčová slova anglicky

p-CrkL; chronic myeloid leukemia; imatinib

Štítky

cbia-web

Změněno: 2. 3. 2018 10:12, Mgr. Pavel Šimara, Ph.D.

Anotace

V originále

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Návaznosti

GBP302/12/G157, projekt VaV

Název: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

Investor: Grantová agentura ČR, Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

ŠIMARA, Pavel; Martina PETERKOVÁ; Stanislav STEJSKAL; Michaela POTĚŠILOVÁ; Irena KRONTORÁD KOUTNÁ; Zdeněk RÁČIL; Filip RÁZGA; Tomáš JURČEK; Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, roč. 53, č. 8, s. 1627-1629. ISSN 1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2012.656104.

@article{979222,
   author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří},
   article_location = {England},
   article_number = {8},
   doi = {https://doi.org/10.3109/10428194.2012.656104},
   keywords = {p-CrkL; chronic myeloid leukemia; imatinib},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & lymphoma},
   title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112},
   volume = {53},
   year = {2012}
}

TY  - JOUR
ID  - 979222
AU  - Šimara, Pavel - Peterková, Martina - Stejskal, Stanislav - Potěšilová, Michaela - Krontorád Koutná, Irena - Ráčil, Zdeněk - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Mayer, Jiří
PY  - 2012
TI  - BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
JF  - Leukemia & lymphoma
VL  - 53
IS  - 8
SP  - 1627-1629
EP  - 1627-1629
PB  - Informa Healthcare
SN  - 10428194
KW  - p-CrkL
KW  - chronic myeloid leukemia
KW  - imatinib
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
L2  - http://www.ncbi.nlm.nih.gov/pubmed/22233112
N2  - In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
ER  -

ŠIMARA, Pavel; Martina PETERKOVÁ; Stanislav STEJSKAL; Michaela POTĚŠILOVÁ; Irena KRONTORÁD KOUTNÁ; Zdeněk RÁČIL; Filip RÁZGA; Tomáš JURČEK; Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50\%{} inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, roč.~53, č.~8, s.~1627-1629. ISSN~1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2012.656104.

Přehled o publikaci